Valuation models
price $82.29 · as of Nov 2, 2026
DCF · Perpetuity growth · 5yused36.62 – 47.9941.5198% overvaluedDCF · Perpetuity growth · 10y44.41 – 58.2650.3763% overvaluedDCF · EBITDA exit · 5y67.75 – 73.5270.5617% overvaluedDCF · EBITDA exit · 10y70.03 – 81.2775.399% overvaluedP/E · own history120.42 – 353.31223.2463% undervaluedPEG—51.2061% overvaluedEV/EBITDA · peers2.17 – 54.3628.26191% overvaluedEV/Revenue · peers14.06 – 291.92143.1243% undervaluedEarnings power value2.22 – 2.462.323447% overvaluedWall St. consensus target—100.0018% belowCost of capital (WACC)—10.12%—
DCF · Perpetuity growth · 5y leads for a high-growth company — positive operating income and three years of positive free cash flow. How the headline model is chosen.
Model value · DCF · Perpetuity growth · 5y
41.51
Dexcom closed at $82.29 — overvalued by 98% vs model.
36.62the model's range47.99
DCF · Perpetuity growth · 5y leads for a high-growth company — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.
Other models
2.32 – 223.24
Wall St. target
100.00 18% below
Above model, 1y
29 of 30 days
How it is valued
Valued asHigh growth
Moderate growth (~13% recent)Moderate margins (18% net margin)Highly cyclical earnings
Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; how each model works is in the manual.